Position in ABBV
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,928,568
+$591,657 QoQ
Shares Held
7,664
+24.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.59%
of 13F equity value
Holder Rank
#1,993
of 4,153 holders
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ABBV Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026STANCE CAPITAL LLC holds $17,488,887 across 8 Drug Manufacturers - General names. ABBV ranks #3 (11.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AMGN |
Amgen Inc
|
13,480 | $4,881,377 | |
| 2 | GILD |
Gilead Sciences, Inc.
|
36,089 | $4,559,483 | |
| 3 | ABBV |
AbbVie Inc.
This page
|
7,664 | $1,928,568 | |
| 4 | MRK |
Merck & Co., Inc.
|
14,779 | $1,899,101 | |
| 5 | PFE |
Pfizer Inc
|
78,762 | $1,896,588 | |
| 6 | LLY |
ELI LILLY & Co
|
1,530 | $1,835,128 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
8,240 | $474,788 | |
| 8 | NVO |
Novo Nordisk A S
|
289 | $13,854 |
All Filings in ABBV
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,928,568 | 7,664 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $1,336,911 | 6,147 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $1,425,777 | 6,240 | Shares | Defined | 2026-03-17 | |
| 2025-09-30 | $1,424,897 | 6,154 | Shares | Defined | 2025-11-19 | |
| 2025-06-30 | $1,262,401 | 6,801 | Shares | Defined | 2025-08-22 | |
| 2024-12-31 | $1,715,159 | 9,652 | Shares | Defined | 2025-04-14 | |
| No filing history on record for this holder in this stock. | ||||||